Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Celgene
Summary
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable. * Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted. Exclusion Criteria: Not Applicable Other protocol-defined inclusion/exclusion criteria apply
Interventions
- GeneticGene-modified (GM) T cell therapy
No investigational product will be administered
Locations (200)
- University of Alabama BirminghamBirmingham, Alabama
- Banner MD Anderson Cancer CenterGilbert, Arizona
- Mayo Clinic PhoenixPhoenix, Arizona
- Arizona Cancer CenterScottsdale, Arizona
- Local Institution - 01021Tucson, Arizona
- City Of HopeDuarte, California